跳至主要内容
临床试验/CTRI/2022/03/041109
CTRI/2022/03/041109招募中未知

Efficacy and Safety of Vasopressin Versus Terlipressin as a Second Vasopressor in Critically Ill Cirrhotics With Septic Shock- the VITEL-C Trial.

Institute of Liver and Biliary Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1) Age 18-70 yrs
  • 2) An informed consent from the patient or relative

排除标准

  • 1.Age <18 years and > 70 years
  • 3.Severe sepsis requiring higher dose of noradrenaline ( >1mcg/Kg/min)
  • 4.Myocardial dysfunction, Coronary artery disease, Arrhythmias
  • 5.Peripheral Vascular disease
  • 6.Gut Paralysis
  • 7.Acute on chronic liver failure (ACLF)
  • 8.Hepato-cellular carcinoma (HCC), intrahepatic or extrahepatic malignancy
  • 9.Complete portal vein thrombosis
  • 10.Hepatic vein outflow tract obstruction (HVOTO)
  • 11.Pregnancy
  • 12.Patients with Pa02/FiO2 ratio <150
  • 15.Severe coagulopathy - platelets <20,000 and INR > 4
  • 16.Active Bleed or DIC
  • 17.Patients already on terlipressin or vasopressin in the last 48 hours
  • 18.Extremely moribund patients with an expected life expectancy of less than 24 hours
  • 19.Failure to give informed consent from family members.
  • 20.Patient enrolled in other clinical trial

研究者

相似试验